

1 July 2021

Diaceutics PLC
("Diaceutics" or "the Company")

Issue of Share Options and PDMR Shareholdings

[Diaceutics PLC](#), (AIM: DXRX), the diagnostic commercialisation company for precision testing announces the issue of share options over ordinary shares of £0.002 each in the Company ("Share Options") on 30 June 2021, to certain members of the Company's senior management team and other key staff. These share options have been issued pursuant to certain contractual share-based entitlements in place prior to the Company's IPO and are governed by the rules of the Company's Employee Share Option Plan ("ESOP").

Share Options were granted as follows:

Name	Number of Share Options granted	Total no. of ordinary shares under option post grant	% of existing issued share capital
Damian Thornton (COO and PDMR)	4,200	170,996	0.2%
Susanne Munksted (CPO and PDMR)	4,200	70,672	0.08%

A further 147,000 Share Options were granted to 35 employees, each of whom received 4,200 Share Options.

The Share Options vest in full after three years following date of grant subject to the grantee receiving no more than two "unsatisfactory" performance ratings in their individual performance reviews in the three-year period from the date of grant. The exercise price of the Share Options is £0.002 per share being the nominal value of the share.

Following the grant the total number of share options outstanding granted to the Company's Directors, senior management team and key employees is 2,237,170, representing approximately 2.7% of the Company's current issued share capital of 84,068,923.

Enquiries:

Diaceutics PLC
Philip White, Chief Financial Officer

Via Alma PR

Stifel Nicolaus Europe Limited (Nomad & Broker)
Ben Maddison
Stewart Wallace
Nick Adams

Tel: +44 (0)20 7710 7600

Alma PR
Caroline Forde
Robyn Fisher
Kieran Breheny

Tel: +44(0)20 3405 0205
diaceutics@almapr.co.uk

About Diaceutics

At Diaceutics we believe that every patient should have access to the right treatment at the right time. We provide the world's leading pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX -

The Diagnostic Network®.

DXRX is the world's first diagnostic commercialisation platform for precision medicine, integrating multiple pipelines of real-world diagnostic testing data from a global network of laboratories.

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014						
1 Details of the person discharging managerial responsibilities/person closely associated						
a.	Name	Damian Thornton				
2 Reason for notification						
a.	Position/Status	Chief Operating Officer				
b.	Initial notification/ Amendment	Initial				
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor						
a.	Name	Diaceutics PLC				
b.	LEI	213800VEWQBB39ZB8J81				
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted						
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary shares of £0.002 each ISIN: GB00BJQTV64				
b.	Nature of the transaction	Grant of Share Options				
c.	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>£0.002</td> <td>4,200</td> </tr> </tbody> </table>	Price(s)	Volume(s)	£0.002	4,200
Price(s)	Volume(s)					
£0.002	4,200					
d.	Date of the transaction	30 June 2021				
e.	Place of the transaction	Outside a Trading Venue				

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014		
1 Details of the person discharging managerial responsibilities/person closely associated		
a.	Name	Susanne Munksted
2 Reason for notification		
a.	Position/Status	Chief Precision Officer
b.	Initial notification/ Amendment	Initial
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a.	Name	Diaceutics PLC
b.	LEI	213800VEWQBB39ZB8J81

4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted					
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary shares of £0.002 each ISIN: GB00BJQTGV64				
b.	Nature of the transaction	Grant of Share Options				
c.	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>£0.002</td> <td>4,200</td> </tr> </tbody> </table>	Price(s)	Volume(s)	£0.002	4,200
Price(s)	Volume(s)					
£0.002	4,200					
d.	Date of the transaction	30 June 2021				
e.	Place of the transaction	Outside a Trading Venue				

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHEAKKEDSKFEFA